Next Article in Journal
Methods of the Analysis of Oxylipins in Biological Samples
Previous Article in Journal
Selective Upregulation by Theanine of Slc38a1 Expression in Neural Stem Cell for Brain Wellness
Previous Article in Special Issue
Oroxin B Induces Apoptosis by Down-Regulating MicroRNA-221 Resulting in the Inactivation of the PTEN/PI3K/AKT Pathway in Liver Cancer
Open AccessArticle

AT-MSCs Antifibrotic Activity is Improved by Eugenol through Modulation of TGF-β/Smad Signaling Pathway in Rats

Department of Regenerative Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan
Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt
Department of Anatomy, College of Medicine, Jouf University, Jouf 74311, Saudi Arabia
Department of Histology and Cell Biology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt
Author to whom correspondence should be addressed.
Molecules 2020, 25(2), 348;
Received: 5 December 2019 / Revised: 11 January 2020 / Accepted: 14 January 2020 / Published: 15 January 2020
(This article belongs to the Collection Molecular Medicine)
For hepatic failure, stem cell transplantation has been chosen as an alternative therapy, especially for mesenchymal stem cells (MSCs). The aim of this study was to investigate the effect of eugenol (EUG) on the in vivo antifibrotic activity of adipose tissue-derived MSCs (AT-MSCs) and the underlying mechanism. After characterization of MSCs, rats were divided into five groups, Group 1 (normal control), Group 2 (CCl4), Group 3 (CCl4 + AT-MSCs), Group 4 (CCl4 + EUG) and Group 5 (CCl4 + AT-MSCs + EUG). Biochemical and histopathological investigations were performed. Furthermore, expression of type 1 collagen, α-SMA, TGF-β1, Smad3 and P-Smad3 was estimated. Compared to the single treatment with AT-MSCs, the combination treatment of the fibrotic rats with AT-MSCs and EUG significantly improved the plasma fibrinogen concentration, IL-10 level and proliferating cell nuclear antigen expression, and also significantly decreased the serum levels of liver enzymes, IL-6, IL-1β, TNF-α, type III collagen, hyaluronic acid, hydroxyproline and the TGF-β growth factor. Furthermore, the combination treatment significantly decreased the hepatic expression of fibrotic markers genes (Type 1 collagen and α-SMA) and proteins (α-SMA, TGF-β1 and phospho-Smad3) more than the treatment with AT-MSCs alone. We demonstrated that the combination treatment with EUG and AT-MSCs strongly inhibited the advancement of CCl4-induced hepatic fibrosis, compared with AT-MSCs alone, through TGF-β/Smad pathway inhibition. This approach is completely novel, so more investigations are necessary to improve our perception of the underlying molecular mechanisms accountable for the effects of EUG on the antifibrotic potential of AT-MSCs. View Full-Text
Keywords: AT-MSCs; eugenol; hepatic fibrosis; TGF-β; Smad3; TNF-α; IL-6; α-SMA AT-MSCs; eugenol; hepatic fibrosis; TGF-β; Smad3; TNF-α; IL-6; α-SMA
Show Figures

Figure 1

MDPI and ACS Style

Fathy, M.; Okabe, M.; Saad Eldien, H.M.; Yoshida, T. AT-MSCs Antifibrotic Activity is Improved by Eugenol through Modulation of TGF-β/Smad Signaling Pathway in Rats. Molecules 2020, 25, 348.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop